Loading...
Loading...
PDSB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 15.1K |
| Gross Profit | -15.1K |
| Operating Expense | 8,684.3K |
| Operating I/L | -8,684.3K |
| Other Income/Expense | -512.8K |
| Interest Income | 675.2K |
| Pretax | -9,197.1K |
| Income Tax Expense | -869.2K |
| Net Income/Loss | -8,327.9K |
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company specializing in developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101 (HPV16), is in Phase II clinical trial for the treatment of recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, including PDS0102, PDS0103, and PDS0104, targeting prostate, breast, ovarian, colorectal, lung, and melanoma cancers. Additionally, PDS Biotechnology is working on vaccines for tuberculosis, influenza, and COVID-19. The company has license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH.
